CLYM
Climb Bio (CLYM)
$25
About Climb Bio (CLYM)
Climb Bio, Inc. operates as a clinical-stage biotechnology company. It develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wellesley Hills, MA.
Details
Daily high
$4.52
Daily low
$3.79
Price at open
$4.52
52 Week High
$4.82
52 Week Low
$1.05
Market cap
315.0M
Dividend yield
0.00%
Volume
3.2M
Avg. volume
2.3M
P/E ratio
-6.15
Climb Bio News
Details
Daily high
$4.52
Daily low
$3.79
Price at open
$4.52
52 Week High
$4.82
52 Week Low
$1.05
Market cap
315.0M
Dividend yield
0.00%
Volume
3.2M
Avg. volume
2.3M
P/E ratio
-6.15